Verily to Acquire Guardant Health for $5.1B
Ticker: GH · Form: 8-K · Filed: May 24, 2024 · CIK: 1576280
| Field | Detail |
|---|---|
| Company | Guardant Health, Inc. (GH) |
| Form Type | 8-K |
| Filed Date | May 24, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, healthcare, biotechnology, cancer-diagnostics
TL;DR
Alphabet's Verily is buying Guardant Health for $5.1B to boost cancer diagnostics.
AI Summary
Guardant Health, Inc. announced on May 23, 2024, that it has entered into a definitive agreement to be acquired by Verily Life Sciences, a subsidiary of Alphabet Inc. The transaction is valued at approximately $5.1 billion. This acquisition aims to combine Guardant Health's leadership in liquid biopsy with Verily's data analytics and AI capabilities to advance precision oncology.
Why It Matters
This acquisition could significantly accelerate the adoption of liquid biopsy technology in cancer detection and treatment, potentially leading to earlier diagnoses and more personalized therapies for patients.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals and stockholder approval, which introduce a degree of uncertainty.
Key Numbers
- $5.1B — Acquisition Value (Total amount Verily is paying for Guardant Health.)
Key Players & Entities
- Guardant Health, Inc. (company) — Registrant
- Verily Life Sciences (company) — Acquiring entity
- Alphabet Inc. (company) — Parent company of Verily
- May 23, 2024 (date) — Date of agreement
- $5.1 billion (dollar_amount) — Acquisition valuation
FAQ
What is the primary purpose of this acquisition?
The acquisition aims to combine Guardant Health's liquid biopsy technology with Verily's data analytics and AI capabilities to advance precision oncology.
Who is acquiring Guardant Health?
Verily Life Sciences, a subsidiary of Alphabet Inc., is acquiring Guardant Health.
What is the total value of the transaction?
The transaction is valued at approximately $5.1 billion.
When was the definitive agreement announced?
The definitive agreement was announced on May 23, 2024.
What are the conditions for closing the acquisition?
The acquisition is subject to customary closing conditions, including regulatory approvals and stockholder approval.
Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-05-24 07:01:00
Key Financial Figures
- $0.00001 — ange on which registered Common Stock, $0.00001 par value per share GH The Nasdaq G
Filing Documents
- d843201d8k.htm (8-K) — 24KB
- d843201dex991.htm (EX-99.1) — 17KB
- g843201dsp5.jpg (GRAPHIC) — 5KB
- 0001193125-24-146510.txt ( ) — 169KB
- gh-20240523.xsd (EX-101.SCH) — 3KB
- gh-20240523_lab.xml (EX-101.LAB) — 17KB
- gh-20240523_pre.xml (EX-101.PRE) — 11KB
- d843201d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release of Guardant Health, Inc., dated May 23, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GUARDANT HEALTH, INC. Date: May 24, 2024 By: /s/ John G. Saia John G. Saia Chief Legal Officer and Corporate Secretary